Michael Georgetson, MD

Care Provider Overall: 
5
Patient Ratings: 
61
  • Clinical Details
  • Education
  • News & Video
  • Clinical Trials
Hospital Privileges: 
  • Guthrie Corning Hospital
  • Guthrie Robert Packer Hospital
  • Guthrie Troy Community Hospital
Clinical Interests: 
  • Dysphagia
  • ERCP
  • Esophageal Diseases
  • Gastrointestinal Bleeding
  • Gastrointestional Neoplasia

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of Recommending Care Provider: 
5
Patients' Confidence in Care Provider: 
5
Time Care Provider Spent with Patient: 
5
Care Provider Spoke Using Clear Language: 
5
Care Provider Efforts to Include in Decisions: 
5
Care Provider's Concern for Questions and Worries: 
5
Care Provider's Explanations of Condition/Problem: 
5
Care Provider Information About Medications: 
5
Care Provider Instructions for Follow-Up Care: 
5
Care Provider's Friendliness and Courtesy: 
5
Residency: 
  • Robert Packer Hospital, Sayre, Pa.
Certification: 
  • American Board of IM/Gastroenterology
Education: 
  • Jefferson Medical College, Philadelphia, Pa.
Fellowship: 
  • Robert Packer Hospital, Sayre, Pa.
  • Fellow of the American College of Gastroenterology (FACG)
Department: Gastroenterology
Diagnosis: Gastrointestinal - Crohn's
Principal Investigator: Georgetson MD, FACG, Michael
Sponsor: Salix
Details (Identifier #): NCT02240121
Title: A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional Study to Assess the Efficacy and Safety of Rifaximin Delayed Release Tablets for the Induction and Maintenance of Remission in Subjects with Active Moderate Crohn's Disease (RECD3125)
Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Georgetson MD, FACG, Michael
Sponsor: Janssen
Details (Identifier #): NCT02407236
Title: CNTO1275UCO3001, A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis